LAEKNA-B (02105) announced that the group has commenced patient enrollment for the Phase I single ascending dose (SAD) study of LAE103, a self-developed ActRIIB monoclonal antibody, in Australia.

As of the date of this announcement, the first subject has completed dosing.

This SAD study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LAE103 (administered subcutaneously) in healthy subjects who are overweight or have obesity.

The group aims to announce the topline data from this SAD study in the third quarter of 2026.

The group is committed to introducing this precision therapy into areas of cardiovascular and metabolic diseases with significant unmet medical needs, such as obesity, sarcopenia, and heart failure.